Neurocrine Biosciences, Inc.
DELTAX CAPITAL | PUBLIC COMPANY RESEARCH
SEPTEMBER 14 2026
Neurocrine Biosciences (NASDAQ: NBIX) develops and sells medicines for neurological and endocrine conditions. Our research examines whether its expanding product portfolio can produce durable cash per share after commercial costs and continuing research investment.
WHAT WE FOUND.
Ingrezza funds the transition. The treatment for tardive dyskinesia and Huntington’s chorea generated about 88% of 2025 revenue. Pricing concessions, potential Medicare negotiation, and competition from Teva’s Austedo can absorb demand growth.
Crenessity offers credible diversification. Clinical evidence and early sales support its role in classic congenital adrenal hyperplasia (CAH). The base forecast of $1.94 billion in 2030 sales requires substantial growth in continuing paid treatment.
Acquisitions and research must earn their cost. Vykat XR’s modeled acquisition cash flows fall short of the identified outlay in the base case. The larger research budget, including direclidine and osavampator, must translate clinical progress into profitable medicines.
The base discounted cash flow estimate was $188.54 per share at a 10% required return, compared with the $156.22 closing price on September 11, 2026. That estimate depends on demanding growth and research assumptions. Crenessity activity 15% below base and recurring research, selling, and administrative costs 10% higher produced $155.78 at the same rate.
Read the full Neurocrine Biosciences research report (PDF)
Prepared by Matthew Schaller, Founder and Chief Investment Officer, DeltaX Capital LLC, a South Carolina-registered investment adviser serving the Charleston area.
General, impersonal research; not individualized investment advice or a recommendation to buy, sell, or hold. Valuation estimates are not price targets or predictions.